You are here

Article Text

Article menu

Download PDFPDF

Abstracts of Poster and e-Poster Presentations
PA-80 Specificity of serological screening tests for diagnosis of gambiense human African trypanosomiasis in Côte d’Ivoire and Guinea
Free
  1. Martial Kassi N’Djetchi1,
  2. Oumou Camara2,
  3. Mathurin Koffi1,
  4. Mamadou Camara2,
  5. Dramane Kaba3,
  6. Traoré Barkissa Mélika1,
  7. Minayégninrin Koné1,
  8. Bamoro Coulibaly3,
  9. Guy Pacôme Adingra3,
  10. Aissata Soumah2,
  11. Mohamed Diaby Gassama2,
  12. Abdoulaye Dansy Camara2,
  13. Bruno Bucheton2,4,
  14. Vincent Jamonneau3,4,
  15. Jean-Mathieu Bart2,4,
  16. Sylvain Biéler5,
  17. Veerle Lejon4
  1. 1Université Jean Lorougnon Guédé, Côte d’Ivoire
  2. 2PNLMTN-PCC – Ministère de la Santé, Guinea
  3. 3Institut Pierre Richet, Côte d’Ivoire
  4. 4Institut de Recherche pour le Développement, France
  5. 5Foundation for Innovative New Diagnostics, Switzerland

Abstract

Background Serological tests play a crucial role to diagnose gambiense human African trypanosomiasis (HAT) by preselecting individuals for microscopic examination, and, in the near future, by directly identifying patients for treatment. Variability in reported specificities, the introduction of new rapid diagnostic tests (RDT) and the hypothesis that malaria decreases RDT specificity, led us to evaluate the specificity of 5 HAT screening tests.

Methods Venous blood samples from 1095 individuals from Côte d’Ivoire and Guinea were tested with commercial (Bioline HAT 2.0, HAT Sero-K-SeT, CATT/T.b. gambiense) and experimental (HAT Sero-K-SeT 2.0, DCN) HAT screening tests and with a malaria RDT. Individuals negative with all 5 HAT tests were considered HAT free, while positives underwent microscopy. HAT case definition was based on trypanosome detection by microscopy.

Results One HAT case was detected. Test specificities (n=1094) were: CATT/T.b. gambiense [98.9% (98.1–99.4%), p<0.0001] > HAT Sero-K-SeT [86.7% (84.5–88.5%), p<0.002] > Bioline HAT 2.0 [82.1% (79.7–84.2%), p=0.0113] > HAT Sero-K-SeT 2.0 [78.5% (76.0–80.9%)] and DCN [78.2% (75.7–80.6%)]. Bioline HAT 2.0 and DCN include 2 test lines, and specificities of line 1 [respectively 83.7% (81.4–85.8%) and 80.6% (78.2–82.9%)], corresponding to ISG-65, were significantly lower (p&t;0.0001) than with line 2 [respectively 95.8% (94.4–96.8%) and 94.5% (93.0–95.7%)]. The ISG-65 line therefore significantly decreased overall test specificity. Although all the HAT tests were less specific in malaria positive than in malaria negative individuals, differences (p values >0.08) were not significant.

Conclusion CATT/T.b. gambiense is more specific than HAT RDTs. The HAT Sero-K-SeT is more specific than second generation RDTs which all contain ISG-65, either as a separate test line (Bioline HAT 2.0 and DCN) or within a single “mixed antigen” test line (HAT Sero-K-SeT 2.0). To improve specificity, removing ISG-65 from experimental RDTs or ignoring the ISG-65 line should be considered, if test sensitivity is not significantly impacted.

https://doi.org/10.1136/bmjgh-2023-EDC.78

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.